Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Hold” by Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been assigned an average rating of “Hold” from the twelve analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $15.3333.

A number of research analysts have recently issued reports on AARD shares. Wall Street Zen raised Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Morgan Stanley reissued an “underweight” rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a report on Monday, July 20th. BTIG Research lowered Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd.

Aardvark Therapeutics News Summary

Here are the key news stories impacting Aardvark Therapeutics this week:

• Negative Sentiment: Multiple securities class-action notices allege that Aardvark and certain executives and directors made materially misleading statements about ARD-101, including claims that the drug was “99% gut-restricted,” had no serious adverse events and could produce Phase 3 data in early 2026. The allegations have not been proven in court. Levi & Korsinsky AARD investor alert
• Negative Sentiment: The lawsuits cite cardiac observations that paused the HERO trial and led the FDA to impose a full clinical hold. These developments raise uncertainty about ARD-101’s safety, development timeline, regulatory approval prospects and potential future financing needs. SueWallSt AARD deadline alert
• Negative Sentiment: The legal actions seek damages under federal securities laws for investors who bought shares in or traceable to Aardvark’s February 2025 IPO, or purchased Aardvark securities during periods generally covering February 2025 through May 14, 2026. Additional firms issued substantially similar notices on September 1–2, increasing visibility of the litigation. Hagens Berman AARD class action notice
• Neutral Sentiment: Investors have until October 13, 2026, to seek appointment as lead plaintiff. The deadline is procedural and does not determine the merits of the allegations, but it may keep litigation in focus for shareholders. Wolf Haldenstein AARD lawsuit notice

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock opened at $5.95 on Friday. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The company has a fifty day moving average of $6.31 and a 200-day moving average of $5.83. The stock has a market capitalization of $130.21 million, a price-to-earnings ratio of -1.85 and a beta of 3.75.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. On average, equities research analysts forecast that Aardvark Therapeutics will post -3.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AARD. Citadel Advisors LLC raised its holdings in Aardvark Therapeutics by 5.9% during the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock valued at $18,073,000 after buying an additional 76,151 shares during the last quarter. Laurion Capital Management LP increased its position in shares of Aardvark Therapeutics by 6.1% in the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after acquiring an additional 60,653 shares during the period. Vanguard Group Inc. increased its position in shares of Aardvark Therapeutics by 20.6% in the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after acquiring an additional 94,744 shares during the period. Millennium Management LLC increased its position in shares of Aardvark Therapeutics by 51.2% in the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock valued at $6,344,000 after acquiring an additional 163,717 shares during the period. Finally, SymBiosis Capital Partners LLC bought a new position in shares of Aardvark Therapeutics during the fourth quarter valued at about $6,255,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.